SeqLL Challenging its Tuesday High

(24/7 MARKET NEWS) – On Tuesday we covered SeqLL’s (NASDAQ:SQL) announcement that it entered a two-year Cooperative Research and Development Agreement (CRADA) with the FBI to evaluate and determine the forensic capabilities of direct RNA sequencing using SeqLL’s True Single Molecule Sequencing (tSMS(R)) platform.

SeqLL was at $1.00, when we covered their news, and we stated that if broke through the $1.20-1.27 resistance level, on strong volume, it could try to challenge its 52-week high of $1.75. It not only blew through the $1.27 resistance, it blew through the $1.75 52-week high and topped out at $2.40, before closing at $1.54, up $1.0005 (+185.45%), volume of 106,134,639 shares traded.

After trading significantly lower the next two days, SeqLL is trading much higher in this morning’s premarket. It nearly took out its 52-week high earlier this morning, hitting $2.39 and is now at $1.87, up $1.13 (122.61%), on 6.9 million premarket shares traded.            

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.